| 000 | 04014nlm1a2200481 4500 | ||
|---|---|---|---|
| 001 | 659730 | ||
| 005 | 20231030041639.0 | ||
| 035 | _a(RuTPU)RU\TPU\network\28501 | ||
| 035 | _aRU\TPU\network\28473 | ||
| 090 | _a659730 | ||
| 100 | _a20190326a2018 k y0engy50 ba | ||
| 101 | 0 | _aeng | |
| 102 | _aUS | ||
| 135 | _adrcn ---uucaa | ||
| 181 | 0 | _ai | |
| 182 | 0 | _ab | |
| 200 | 1 |
_aComparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors _fA. G. Vorobjeva (Vorobyeva), O. G. Bragina, M. Altai [et al.] |
|
| 203 |
_aText _celectronic |
||
| 300 | _aTitle screen | ||
| 320 | _a[References: 47 tit.] | ||
| 330 | _aHigh expression of human epidermal growth factor receptor 2 (HER2) in breast and gastroesophageal carcinomas is a predictive biomarker for treatment using HER2-targeted therapeutics (antibodies trastuzumab and pertuzumab, antibody-drug conjugate trastuzumab DM1, and tyrosine kinase inhibitor lapatinib). Radionuclide molecular imaging of HER2 expression might permit stratification of patients for HER2-targeting therapies. In this study, we evaluated a new HER2-imaging probe based on the designed ankyrin repeat protein (DARPin) 9_29. DARPin 9_29 was labeled with iodine-125 by direct radioiodination and with [99mTc]Tc(CO)3using the C-terminal hexahistidine tag. DARPin 9_29 preserved high specificity and affinity of binding to HER2-expressing cells after labeling. Uptake of [125I]I-DARPin 9_29 and [99mTc]Tc(CO)3-DARPin 9_29 in HER2-positive SKOV-3 xenografts in mice at 6 h after injection was 3.4 ± 0.7 %ID/g and 2.9 ± 0.7 %ID/g, respectively. This was significantly () higher than the uptake of the same probes in HER2-negative Ramos lymphoma xenografts, 0.22 ± 0.09 %ID/g and 0.30 ± 0.05 %ID/g, respectively. Retention of [125I]I-DARPin 9_29 in the lung, liver, spleen, and kidneys was appreciably lower compared with [99mTc]Tc(CO)3-DARPin 9_29, which resulted in significantly () higher tumor-to-organ ratios. The biodistribution data were confirmed by SPECT/CT imaging. In conclusion, radioiodine is a preferable label for DARPin 9_29. | ||
| 461 | _tContrast Media & Molecular Imaging (CMMI) | ||
| 463 |
_tVol. 2018 _v[6930425, 11 p.] _d2018 |
||
| 610 | 1 | _aэлектронный ресурс | |
| 610 | 1 | _aтруды учёных ТПУ | |
| 610 | 1 | _aсравнительная оценка | |
| 610 | 1 | _aрадиоактивный йод | |
| 610 | 1 | _aтехнеций | |
| 610 | 1 | _aрадионуклидная диагностика | |
| 610 | 1 | _aзлокачественные опухоли | |
| 701 | 1 |
_aVorobjeva (Vorobyeva) _bA. G. _cspecialist in the field of medical technology _cSenior Researcher, Oncoteranostika Research Center, Tomsk Polytechnic University, Ph.D _f1990- _gAnzhelika Grigorjevna _2stltpush _3(RuTPU)RU\TPU\pers\46556 |
|
| 701 | 1 |
_aBragina _bO. G. _gOlga Gennadjevna |
|
| 701 | 1 |
_aAltai _bM. _gMohamed |
|
| 701 | 1 |
_aOrlova _bA. _gAnna |
|
| 701 | 1 |
_aSchulga _bA. A. _gAleksey Anatoljevich |
|
| 701 | 1 |
_aProshkina _bG. M. _gGalina Mikhaylovna |
|
| 701 | 1 |
_aChernov _bV. I. _cspecialist in the field of medical technology _clead engineer of Tomsk Polytechnic University, doctor of medical sciences _f1962- _gVladimir Ivanovich _2stltpush _3(RuTPU)RU\TPU\pers\34191 |
|
| 701 | 1 |
_aTolmachev _bV. M. _gVladimir Mikhaylovich |
|
| 701 | 1 |
_aDeev _bS. M. _cbiologist _cthe expert of Tomsk Polytechnic University, doctor of biological Sciences _gSergey Mikhaylovich _2stltpush _3(RuTPU)RU\TPU\pers\39299 |
|
| 712 | 0 | 2 |
_aНациональный исследовательский Томский политехнический университет (ТПУ) _bФизико-технический институт (ФТИ) _bЛаборатория № 31 ядерного реактора (Лаборатория № 31 ЯР) _h6471 _2stltpush _3(RuTPU)RU\TPU\col\20054 |
| 801 | 2 |
_aRU _b63413507 _c20210204 _gRCR |
|
| 856 | 4 | _uhttps://doi.org/10.1155/2018/6930425 | |
| 942 | _cCF | ||